Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.

Radiology. Imaging cancer·2026
Same author

Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [<sup>225</sup>Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Widespread Prostate Cancer Osseous Metastases: Negative on <sup>18</sup>F-Piflufolastat PET but Positive on <sup>18</sup>F-Fluciclovine PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.

Journal for immunotherapy of cancer·2026
Same author

ACR Appropriateness Criteria® Staging and Follow-Up of Adrenal Cancer.

Journal of the American College of Radiology : JACR·2026
Same author

ACR Appropriateness Criteria® Breast Implant Evaluation: Update 2025.

Journal of the American College of Radiology : JACR·2026

Related Experiment Video

Updated: Apr 6, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Targeted immunoPET imaging of multiple myeloma.

Gary A Ulaner1, Ola Landgren2

  • 1Molecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, CA; Radiology and Cancer Biology, University of Southern California, Los Angeles, CA.

Seminars in Hematology
|April 5, 2026
PubMed
Summary

Immunologically based positron emission tomography (immunoPET) offers a superior, noninvasive method for imaging multiple myeloma. This advanced technique improves detection and assessment of disease burden compared to current standards.

Keywords:
BCMACD38CD46CXCR4ImmunoPETMultiple myeloma

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.5K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K

Related Experiment Videos

Last Updated: Apr 6, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.5K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Immunology

Background:

  • Current imaging methods for multiple myeloma, such as fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT), are suboptimal and may miss up to 50% of lesions.
  • Immunologically based positron emission tomography (immunoPET) utilizes antibodies or antibody fragments labeled with radioisotopes to target specific myeloma antigens.

Purpose of the Study:

  • To review the concept of immunoPET, current agents in development for multiple myeloma, and their potential clinical applications.
  • To highlight immunoPET's role in improving the detection, localization, quantification, and residual disease evaluation of multiple myeloma.
  • To discuss immunoPET's potential in predicting treatment response and its application in radioligand therapy.

Main Methods:

  • Review of current literature on immunoPET agents targeting antigens like CD38, BCMA, and CXCR4 in multiple myeloma.
  • Discussion of immunoPET's noninvasive, whole-body assessment capabilities compared to traditional biopsies.
  • Exploration of immunoPET's utility in disease detection, biopsy targeting, and post-therapy residual disease evaluation.

Main Results:

  • ImmunoPET agents target highly expressed myeloma antigens (CD38, BCMA, etc.), enabling precise detection and localization.
  • ImmunoPET provides noninvasive, whole-body assessment of multiple myeloma burden, outperforming conventional imaging.
  • ImmunoPET shows promise in predicting response to targeted therapies and can be adapted for radioligand therapy.

Conclusions:

  • ImmunoPET represents a significant advancement in multiple myeloma imaging, offering improved accuracy and comprehensive disease assessment.
  • Its applications extend from early detection to treatment response prediction and potential therapeutic interventions.
  • Further development and clinical investigation of immunoPET agents are crucial for optimizing multiple myeloma management.